Deep Dive Digital Magazine
The Deep Dive Digital Magazine has fresh content on pharma and healthcare industry trends in an innovative and interactive layout, serving a circulation in excess of 40,000 with every issue.
Content can be written for you by pharmaphorum or supplied by you. We also offer responsive banner advertising through the journal within all non-paid content or a high-profile Deep Dive issue sponsorship. All options include a dedicated support marketing plan for 2 months post publication.
Deep Dive: Digital Health Innovation
This bespoke edition of pharmaphorum’s regular Deep Dive digital magazine investigates the digital health ecosystem with input from an expert cast of investors, start-up founders, pharma executives and many more.
Produced in partnership with Healthware International, Deep Dive: Digital Health Innovation talks about the convergence of digital and traditional medicine, the pace of healthcare technology adoption and the transformation of patient outcomes.
There’s advice on how to use digital technology to support patients on their empowerment journeys and how pharmaceutical companies can best work with health tech start-ups.
Continuing that theme the issue features Pfizer on its work with start-ups and Bayer on how its innovation team is injecting an entrepreneurial spirit to the pharma company’s work.
The issue also looks at the development and potential of digital therapeutics, and emerging regulatory approaches within this exciting area.
As a whole the issue brings a wide range of insights to the core themes that will be covered at November’s Frontiers Health event in Berlin.
The current issue
Deep Dive Oncology special: reflections on ASCO
Welcome to a special edition of Deep Dive focusing exclusively on Oncology. This is the first of a series of Deep Dive issues which combine unique insight and opinion with the best from a leading medical conference.
The conference in question this time around is the 2018 American Society of Clinical Oncology (ASCO) conference, which pharmaphorum’s senior report Richard Staines attended in June.
Highlights from our Oncology special edition include an interview with Merck & Co’s research chief Roy Baynes about how there could be more to come from Keytruda, plus further insights from ASCO into CAR-T cell therapies for drug cancer, reviews of the latest research in prostate and breast cancer drugs and how digital technology could help diagnose cancer earlier. Other highlights include an article from Witty Health on how blockchain technology could transform cancer care, whilst Matt Coffey, president and chief executive officer at Oncolytics Biotech talks about the oncolytic virus renaissance and how it is improving the efficacy of current immunotherapies. Plus, health economist Leela Barham reviews the latest ways to assess the worth of new cancer drugs, and the implications for pharma and patients too.
Our future Deep Dives
late November / early December 2018: Disruptive Technologies
February 2019: R&D Innovation
April 2019: Access & Commercialisation
June 2019: Oncology
September 2019: Sales & Marketing Innovation
October 2019: Digital Health
December 2019: Patient Engagement
Want to get involved? Contact Adam Jeffery at +44 (0)1932 339 263, email@example.com
Future Pharma 2018
Welcome to the latest edition of pharmaphorum’s Deep Dive magazine, once again bringing expert insight and analysis together to delve into a critical industry topic.
This issue brings forth evidence of what the likely future is for our industry, what this means for healthcare and how pharma can best navigate the sea change ahead to ensure a successful and sustainable future.
Highlights from the Future Pharma 2018 edition include:
Chris Molloy of the Medicines Discovery Catapult explains why the future of medical innovation lies with the industry’s SMEs
Karen Taylor of Deloitte offers six predictions for the course of our industry into 2022, both evolutionary and revolutionary.
How Blockchain could enable a truly global healthcare ecosystem.
And a look into real-world examples of how nanotechnology is now advancing medicine, and the challenges faced.
Patient Centricity 2018
The phrase ‘patient centricity’ has been a buzzword for some time in the industry, but how many companies are merely paying it lip service? Are there firms that truly understand and have taken steps to reorganise their approach, internally and externally?
Though patient organisations and charities may feel pharma has a long way to go, this edition of Deep Dive features many examples where companies have listened and partnerships have resulted in improvements to patients’ lives – and pharma’s bottom line.
Read this issue for advice from the experts on how to define patient centricity, build trust and develop strong relationships.
David Mitchell, President of Patients for Affordable Medicines, speaks to Andrew McConaghie about drug pricing in the US.
Alastair Kent, ambassador for Genetic Alliance UK, points the way forward with patient engagement.
Oliver Childs and Shai Blackwell of Anatomy Health offer guidance.
NexGen’s Richard Evans and Emma Sutcliffe champion the cause of patient centricity.
Duncan Arbour, Alex Brock and Marie Emms of Syneos Health explain why pharma needs to shift its mindset.
Linda Verplanck of Kantar Health says research must deliver information that transforms real-world outcomes.
How the National Rheumatoid Arthritis Society is helping people manage their conditions better with interactive video.
Matt Arnold of DRG presents the benefits of deep assessment of real-world data.
Caroline Benson, of the PM Society’s Patient Engagement Interest Group (PEIG) and Co-Founder of Cuttsy+Cuttsy, outlines the actions to take in this 10-step guide.
DataArt’s Ivan Pantykin on the evolution of an app for children with chronic conditions.
Tom Kottler of HealthPrize Technologies talks about avoidable annual losses in pharma and what actions to take to recover that revenue.
Scott Williams & Madeleine Starr talk about the Embracing Carers initiative that is supported by Merck.
Vanessa dos Reis Ferreira expands on how her company is focused on understanding patient needs.
Neil McGregor-Paterson provides the answer – and expands on why it is important.
Leigh Thomas of BBI Solutions thinks allowing the pubic to self-test will help them and health systems.
There are an increasing number of digital companies with solutions entering the healthcare sector. These digital companies capture and analyse data, that can be used to improve clinical trial recruitment to real-world outcomes.
Patients and healthcare providers have technology to monitor symptoms and drug benefits over time. This is thanks to the abilities of hand-held and wearable devices.
Some pharma companies are blending digital into their company processes and others do not know where to start. This Deep Dive edition hears from the experts about how to navigate the challenges that still remain. There are some highlights of the companies and organisations shaking up the health space.
IQVIA examines the trends in three areas: innovation, evidence and adoption.
Nelia Padilla and Hilary Armstrong of IQVIA on the promise, and reality, of digital health.
pharmaphorum’s Andrew McConaghie on the rise of the machines.
Digital expert Alex Butler on improving teamwork and patient understanding.
Joe Miles of SAP discusses the issue with pharmaphorum’s Richard Staines.
Fredrik Debong on his start-up being acquired by Roche.
Nurse, digital and patient together, say Rebecca Galbraith and John Procter of IQVIA.
M3’s Paul Rice examines the evidence
Zephyr’s William King on managing and exploiting data.
Roche Pipeline’s Karen Lightning-Jones on data management.
Ed Hammerton of inVentiv Health Communications provides a step-by-step guide.
Pharmaphorum’s Marco Ricci reviews latest start-ups and themes at the recent event.
Five leaders in the digital health community give their summaries.
Communications director Tim Parry on the organisation’s use of the latest technology.
John Grumitt of Diabetes UK and Changing Health on how digital health innovators can help pharma address medical needs.
Market Access 2017
Ultimately, market access is about ensuring effective treatments reach the people who need them. There are many components that must fit together along that journey, as explored by our expert contributors in this edition.
Just some of the themes include: the real impact of a Health Technology Assessement (HTA) decision, the promise of the ‘MINT’ countries (Mexico, Indonesia, Nigeria and Turkey), a step-by-step guide to the generation and use of real-world data, filling the gap between drug development and implementation, the pivotal role of Pharmacy Benefit Managers in the US, as well as the challenges in improving rare disease treatment and biosimilars uptake.
pharmaphorum’s Richard Staines looks at the EMA’s scheme 18 months on.
Wendy Gidman & Ruth Howells of DRG Abacus research the impact of a positive HTA.
Craig Bradley of MAIG reviews the PM Society survey results.
Company president Jon Williams on issues impacting access to new therapies.
Evidera’s Dimitra Lambrelli and Krista A Payne on use of real-world evidence.
Research Partnership’s Rachel Howard & Sue Rees investigate the pros and cons.
Leela Barham reviews the evidence.
QuintilesIMS’ Rebecca Galbraith & Gavin Jones guide you through the steps.
pharmaphorum’s Andrew McConaghie reviews the US situation.
Context Matters’ Judith Rubinstein & Joan Gaffney focus on market access for this brain cancer.
Stefan Bosbach from phamax scrutinises the issues hampering access to the right treatments.
Kirk Shepard of Eisai and Simon Mason of Medmeme on the key issues.
Monique Martin, Tony Lanzone & Michael Iacoviello from inVentiv Health Consulting, consider barriers and benefits.
Partner with patient advocates, says consultant Eric Low.
Ann Single & Neil McGregor-Paterson delve into its importance.
Tahir Amin, of Initiative for Medicines, Access & Knowledge, speaks out.
Future Pharma 2017
Healthcare is facing transformation – tech companies large and small are moving in to the sector and, in turn, pharma is partnering with tech companies to develop novel solutions for patient monitoring, adherence, improving clinical trials, big data analysis, and recording the real-world effects of therapies, to name just a few. Add proactive patients and tailored drug advances and the future looks both exciting and uncertain.
This edition of Deep Dive considers topics ranging from pharmacogenomics and regenerative medicine to the growing importance of the behavioural sciences to current applications for artificial intelligence (AI), augmented reality (AR), virtual reality (VR) and bioelectronics.
Dalvir Gill, CEO of TransCelerate, on healthcare in 2030.
Nexeon’s Will Rosselini talks to our Managing Editor, Linda Banks.
Dolan Desai of Blue Latitude considers the candidates.
Medical Futurist Bertalan Mesko on the ideas that will transform the sector.
pharmaphorum’s technology writer Marco Ricci on applying VR to health.
Sarah Rickwood of QuintilesIMS considers the influencers in medical technology.
Robert Poole and Sandra Gulbicki of McCann on applying the ‘softer sciences’.
Pierre Meulien, CEO of Innovative Medicines Initiative, on the trends.
Preview of the first in a series of thought leader discussions.
Ashley Jaksa & Dan Liden of Context Matters consider the growing influence of HTA.
Ben Doran considers the evolution of precision medicine in cancer.
pharmaphorum’s Andrew McConaghie crunches the numbers.
Kim Hughes of THE PLANNING SHOP offers his tips.
Shahzad Ali of Plasticell on where precision therapies may lead.
Mark Sales of Kantar Health looks at the changing landscape.
Advances in treatments are revolutionising cancer management. But with one in two people likely to be diagnosed with the disease today, are screening and diagnosis swift enough and, for those needing treatment, how effective are the latest tailored drugs?
With more people living longer with cancer, is the wider support infrastructure for patients and carers adequate? And when is the right time for some to stop trying one more drug and focus on quality end-of-life care
This edition examines the latest immuno-oncology techniques, the question of affordability, and the cutting-edge research being funded by Cancer Research UK’s Grand Challenge programme.
Andrew McConaghie of pharmaphorum on the cancer challenge: the quest for a cure is only half the battle.
pharmaphorum’s Richard Staines considers the next wave of cancer therapies.
The future of cancer treatment lies in combinations and partnerships, say Blue Latitude’s Anne Legendre and Frances Hendry.
Health economist Leela Barham examines the cancer drug funding systems in the nations of the UK.
Peter Rutherford of QuintilesIMS outlines the need for comprehensive and tailored support programmes.
Ashley Jaksa of Context Matters assesses the global challenges inhibiting market access.
Linda Banks of pharmaphorum reports on the latest, multi-disciplined, international projects funded through Cancer Research UK’s Grand Challenge awards.
Healthcare at Home’s Nigel Williams, Kate de Lord and Rosie Debelle explain the benefits of care away from the hospital setting.
Pharmaphorum’s Marco Ricci investigates new devices for oncology screening, diagnosis and mental wellbeing.
pharmaphorum’s Linda Banks asks Bowel Cancer UK about its campaigns and home screening programme.
Patient Centricity 2017
What does ‘patient centricity’ really mean? And what does it look like in practice? Can embedding a person-centred approach in an organisation be a win for the company as well as the patient?
The European Patients Forum, European Society for Person Centred Healthcare, Findacure and the EMA’s Patients’ and Consumers’ Working Party, outline examples of best practice and areas for further development, while home care service providers, market researchers and consultants offer expertise in developing patient support programmes, gathering reliable patient insights and examining whether the plethora of health-related apps are both used and of value.
The European Medicines Agency Patients’ & Consumers’ Working Party co-chair on patient power in Europe.
Peter Rutherford and Rebecca Galbraith, of QuintilesIMS, explain how to implement effective patient support programmes.
Nicola Bedlington, Secretary General of the European Patients’ Forum (EPF), highlights examples of best practice in empowerment.
Adherence and outcome support commercially viable for pharma and primary care, suggests app developer Sebastian Gaede.
Sir Jonathan Asbridge, of Healthcare at Home, says a shift to ‘person-centred’ care can help finite budgets and outcomes.
Pharma needs patient voice from earliest stages of product lifecycle, say Claire Fradet Aubignat, Ellie Abery and Helen Mace of Research Partnership.
Ensure patient literature is accessible and, therefore, effective, say Lizzie Perdeaux of Oxford PharmaGenesis and Flóra Raffai of Findacure.
Pharma claims to put patients at the heart of research, but there’s some way to go, say INC Research’s Clare Grace and Christine Phillips.
Nadine van Dongen, of PIP Health, presents a practical guide to planning and running an effective patient support programme.
Pharma needs assistance working out how these new roles look in practice, says Helen Pattison, of Pegasus, an Ashfield company.
Profs Andrew Miles and Sir Jonathan Asbridge, of European Society for Person Centered Healthcare, offer some answers.
Clare Moloney of Atlantis Healthcare on healthcare support systems to promote optimum outcomes.
A doctor with a special interest in MS, Mandy Fry believes GPs see the wider picture.
Flexible approaches needed for paediatric treatments, says Cesare Spadoni of aPODD.
Findacure’s Rick Thompson on the value of focus groups with rare disease patients for mutual benefit.
This issue examines the use of digital technologies in the healthcare space, ranging from management of data and real-world evidence, to industry initiatives, to best practice in social media for optimal marketing and sales, plus how to get the most from gamification and scientific animation.
Read the views of some of the top minds in the field, from companies and organisations including IBM Watson Health, Twitter, the ABPI and EACA, and learn what’s next in the digital revolution.
Kyu Rhee, chief health officer at IBM Watson Health, on the company’s achievements and aspirations in cognitive computing.
Faruk Capan, CEO of Intouch Solutions, says pharma and marketers should partner to understand patients’ needs and offer innovative solutions.
Twitter’s head of marketing, Brian Laker, outlines what companies can do to understand and engage with target markets.
Pharma needs to embrace a proactive ‘social intelligence’ approach, say Cello Health’s Damian Eade and Tim Williams.
Shahid Hanif, Head of Data & Outcomes at the ABPI, highlights the big data initiatives making the UK desirable for R&D.
Roberto Ascione, CEO of Healthware International, calls for a culture of ‘open innovation’ for all to benefit from this new ecosystem.
Chairman and founder of the Games for Health Europe Foundation, Jurriaan van Rijswijk, says promoting happiness benefits health.
Cameron Slayden, CEO and creative director at Cosmocyte, guides us through the animation production process.
Andy Stafford, commercial director at Nitro Digital suggests ways for pharma to enter the new era of customer and patient-centricity.
Consultant Stephen Black says information gleaned from data can make health services safer, more efficient and cost effective.
Kathy Presto and Simon Mason of Medmeme take use of data to the next level, examining medical and pharma outputs.
China’s doctors’ willingness to engage with pharma online is a cause for optimism, reports Adele Li of Kantar Health.
pharmaphorum’s Marco Ricci examines AI’s impact on the pharma and healthcare sectors.
William King, founder and executive chairman of Zephyr Health, on predictive insights and his mission to help life science companies.
In a digital world, pharma must ‘get with the programme’ says Dominic Lyle, Director-General of the European Association of Communications Agencies.
Mike Barlow, Founder & CEO at myHealthPal Group, used his Parkinson’s diagnosis to develop a data tracking app.
Social media communication is often seen as complex and risky, but treat it like face to face, says pharmaphorum connect’s Christian Gardner.
Spotlight on the top digital health trends of 2016 from pharmaphorum’s Marco Ricci.
AI helps understanding of target markets, but pharma needs an overarching strategy, argues Andrée Bates, founder of Eularis.
Technology and a patient-centric/outcomes approach are helping, but data security and ‘app fatigue’ challenging, says Takeda’s Stephanie Bova.
Social media amplifies commentary around new research at medical meetings, but what and who are the biggest influencers?
Market Access 2016
This issue brings you intelligent insights on the topic of market access in a series of in-depth articles and opinion pieces from industry thought leaders, patient group experts and our pharma journalists.
Read a keynote from EFPIA’s director general on how the industry is willing to partner with payers to deliver outcomes-driven, sustainable healthcare and overcome the challenges of rising demand from ageing populations and chronic diseases, hear about new models for improved access, and the specific needs of rare disease communities.
Richard Bergstrom (EFPIA)
Andrew McConaghie (pharmaphorum)
Richard Staines (pharmaphorum)
Claire Bowie (pharmaphorum)
Peter Rutherford (Quintiles)
The Deep Dive Interview: Steven Pearson (ICER) speaks to Andrew McConaghie (pharmaphorum)
Richard Meyer (Healthcare consultant)
Jayasree K Iyer (Access to Medicine Foundation)
Andrew McConaghie (pharmaphorum)
Leela Barham (Economic consultant)
Richard Staines (pharmaphorum)
David Bennett (Marketing consultant)
Paul Mannu, with Tom Atkinson and Jon Gilbert (Cello Health)
Nicola Bedlington (European Patients’ Forum)
Zack Pemberton-Whiteley (Leukaemia Care)